The role of nuclear medicine in monitoring treatment in skeletal malignancy

Seminars in Nuclear Medicine

Volumn 31, Issue 3, 2001, Pages 206-211

  Cook, Gary J R ^a,b   Fogelman, Ignac ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM 47; MEDRONATE TECHNETIUM TC 99M; STRONTIUM 85;

BONE MARROW DISEASE; BONE METASTASIS; BONE SCINTISCANNING; BONE TUMOR; BREAST CANCER; CLINICAL PRACTICE; HUMAN; OSTEOSCLEROSIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW;

EID: 0034967255     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.23527     Document Type: Article

References (42)

1. The anatomy and pathways of skeletal metastases
2. Detection of bone metastases in breast cancer by 18-FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions
3. Bone metastases: Incidence and complications
4. Advanced breast cancer: Use of resources and cost implications
5. Assessment of response to therapy in advanced breast cancer
6. The clinical course of bone metastases from breast cancer
7. Assessment of response of bone metastases to systemic treatment in patients with breast cancer
8. Osseous metastases of breast cancer. Clinical, biochemical, radiographic and scintigraphic evaluation of response to therapy
9. Is the carcino-embryonic antigen test a valid predictor of response to medical therapy in disseminated breast cancer
10. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer
11. Leuprolide therapy for prostate cancer. An association with scintigraphic flare on bone scan
12. The assessment of response to therapy in bone metastases from breast cancer
13. Bone scan flare predicts successful systemic therapy for bone metastases
14. Bone scans with one or two new abnormalities in cancer patients with no known metastases: Frequency and serial scintigraphic behaviour of benign and malignant lesions
15. Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging
16. The pathophysiological basis for skeletal scintigraphy
17. 85Sr local kinetics
18. New criteria for scintigraphic follow-up of bone metastases following radiotherapy. Results of functional scintigraphy using 99mTc-MDP
19. Local and systemic effects of radiation on bone metabolism measured by quantitative SPECT
20. The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer
21. Quantitative bone metastases analysis based on image segmentation
22. Comparison of quantitative and visual detection of new focal bone lesions
23. Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy
24. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer
25. Comparative value of bone scintigraphy and radiography in monitoring tumour response in systemically treated prostatic cancer
26. Utilisation of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy
27. Nuclear bone imaging in metastatic cancer of the prostate
28. Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchidectomy
29. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy
30. Midcourse thallium-201 scintigraphy to predict tumor response in bone and soft-tissue tumors
31. Pentavalent 99Tcm-DMSA imaging in patients with bone metastases
32. FDG uptake, tumour characteristics and response to therapy: A review
33. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
34. Evaluation of the effect of preoperative chemotherapy in bone sarcomas. 99mTc-HMDP in 34 cases
35. Thallium-201 scintigraphy in bone sarcoma: Comparison with gallium-67 and technetium-MDP in the evaluation of the chemotherapeutic response
36. Technetium-99m-MDP scintigraphy and long-term follow-up of treated primary malignant bone tumours
37. Bone scintigraphy in non-surgically treated Ewing's sarcoma at diagnosis and follow-up: Prognostic information of the primary tumour site
38. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas
39. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma
40. Thallium-201 scanning for the evaluation of osteosarcoma and soft tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy
41. 99mTc MIBI SPECT in evaluation of musculoskeletal sarcomas
42. Monitoring of neoadjuvant therapy response of soft tissue and musculoskeletal sarcoma using fluorine-18-FDG PET